医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Augmenix, Inc. Announces the Opening of a New Headquarters in Tokyo, Japan

2018年04月30日 PM04:00
このエントリーをはてなブックマークに追加


 

BEDFORD, Mass. & TOKYO

Augmenix, Inc., a worldwide leader in hydrogel spacing solutions which reduces toxicity associated with radiation therapy, has opened a new company headquarters, Augmenix KK., in Japan.

This newly opened headquarters is located in central Tokyo and will provide customer support for customers throughout greater Japan.

“We are very pleased with the opening of this new office in Tokyo in anticipation of our SpaceOAR® hydrogel market launch and the Ministry of Health, Labor & Welfare (MHLW) national reimbursement decision by the end of the second quarter in 2018,” said Yoshinori Kuratani, General Manager of Augmenix KK. “Thanks to our innovative technology and clinical benefits, we have received positive feedback and many inquiries from physicians across Japan interested in adopting SpaceOAR hydrogel. Our continued expansion will enable more physicians in Japan to offer SpaceOAR hydrogel as an option for men with prostate cancer who want to reduce their risk of radiotherapy side effects.”

ABOUT AUGMENIX, INC.

Augmenix, Inc. is a privately held company based in the Boston, Massachusetts area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, their next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. SpaceOAR hydrogel, the company’s lead product, is a registered trademark of Augmenix, Inc. More information about Augmenix and SpaceOAR hydrogel can be found at http://www.SpaceOAR.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180430005081/en/

CONTACT

Augmenix KK Contact:
Yoshinori Kuratani,
2-7-14 Toranomon,
Minato-ku
Tokyo 105-0001 Japan
Tel: 03-5544-8340
ykuratani@augmenix.com
or
Augmenix,
USA Contact:
April Renzella, 781-902-1621
ARenzella@augmenix.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法